Objectives: Sentinel lymph node (SLN) removal may be a midterm between no and full pelvic dissection in early endometrial cancer. Whereas the use of blue dye alone in SLN detection has a poor accuracy, its integration in an SLN algorithm may yield better results and overcome hurdles such as the requirement of nuclear medicine facility. Methods: Sixty-six patients with clinical stage I endometrial cancer were prospectively enrolled in a multicentre study between May 2003 and June 2009. Patent blue was injected intraoperatively into the cervix. We retrospectively assessed the accuracy of a previously described SLN algorithm consisting of the following sequence: (1) pelvic node area is inspected for removal of all mapped SLN and (2) excision of every suspicious non-SLN, (3) in the absence of mapping in a hemipelvis, a standard ipsilateral lymphadenectomy is then performed. Results: Sentinel nodes were identified in 41 patients (62.1%), mostly in interiliac and obturator areas. None was detected in the para-aortic area. Detection was bilateral in 23 cases (56.1%). Seven patients (10.6%) had positive nodes. The false-negative rate was 40% using SLN detection alone. When the algorithm was applied, the false-negative rate was 14.3%. The use of a SLN algorithm would have avoided 53% of lymphadenectomies Conclusion: Our multicentric evaluation validates the use of a SLN algorithm based on blue-only sentinel node mapping in early-stage endometrial cancer. The application of such SLN algorithm should be evaluated in a prospective context and might lead to decrease unnecessary lymphadenectomies. ORIGINAL STUDY
Whereas the revised 2009 FIGO staging system continues to incorporate lymph node status, 4 the prognostic and therapeutic relevance of performing lymphadenectomy is now more than ever a source of debate. For clinical early-stage endometrial cancer, 2 recent large randomized trials demonstrated that lymph node sampling did not improve overall recurrence nor survival rates and therefore should not be recommended as routine procedure. 5Y7 Nevertheless, some significant limitations make the strength of these conclusions questionable.
8Y10
Even if the risk of nodal involvement seems to be low, approximately 10%, 11, 12 16% to 22% of clinical early-stage endometrial cancers are upstaged after surgical procedures. 13, 14 Therefore, supporters of lymphadenectomy claim that lymph node dissection is the only way to fully stage the disease and to determine which patients are likely to benefit from adjuvant therapy. 10, 15 However, complete lymphadenectomy leads to higher complication rate. 7 These findings emphasize the importance of careful patient selection for lymph node dissection and underline the requirement of developing reliable and less invasive procedures as an alternative to standard lymphadenectomy. Indeed, the European Society for Medical Oncology stratified patients with early-stage disease into 3 risk categories for disease relapse and survival. 16 In accordance with European Society for Medical Oncology stratification, the French guidelines recommend systematic para-aortic and pelvic lymph node dissection for highrisk patients. 17 Lymphadenectomy is not recommended for lowand intermediate-risk groups, whereas sentinel lymph node (SLN) biopsy is introduced as a possible option. Taking advantage from identification and pathological examination of a limited number of nodes, this procedure might represent a midterm between no dissection at all and full dissection.
Two recent prospective studies showed interesting results using cervical dual labeling (patent blue and radiocolloid), with high detection rates (89%Y92%) and acceptable rate of falsenegative results, yielding negative predictive values between 99% and 100%. 18, 19 Lymph node staging was also improved via the detection of micrometastases by ultrastaging (serial section and immunohistochemistry) of a limited number of nodes. 20, 21 However, radiocolloid injection requires nuclear medicine facilities and thus is unsuitable for some institutions. Blue dye single labeling method might theoretically represent an alternative to combined detection but seems in fact not reliable enough, as a result of low detection and high falsenegative rates.
22Y24 Nevertheless, its integration in an algorithm could improve its effectiveness in detecting metastatic endometrial cancer, as supported by Barlin et al 25 in a recent retrospective study.
The aim of this retrospective multi-centric study was to evaluate the reliability of a previously described SLN algorithm based on intraoperative blue dye detection in early-stage endometrial cancer.
PATIENTS AND METHODS
From May 2003 to June 2009, 66 patients with endometrial cancer were enrolled prospectively in a pilot study evaluating blue dye labeling method for SLN detection. Protocol was sent with no restrictions to all the hospitals participating in the cancer network Oncomip, France. To participate in the study, local surgeons had to be experienced in the surgical management of endometrial cancer and in SLN procedure in other malignancies. The inclusion criteria were biopsyconfirmed endometrial cancer, apparent stage I after clinical and radiologic workup. Magnetic resonance imaging (MRI) is standard in the guidelines of the Oncomip network. When it could not be performed (for medical reasons or claustrophobia), preoperative staging was based on pelvic ultrasound and pelvic and abdominal computed tomography. Patients with a history of multiple allergies or a history of anaphylactic reaction to patent blue were excluded.
The study obtained the agreement of the regional institutional review board. All the patients gave written consent after receiving relevant information, including the potential adverse effects of patent blue injection.
Surgical Approach
Surgical treatment included peritoneal washing, SLN procedure, bilateral salpingo-oophorectomy, systematic bilateral pelvic lymphadenectomy, and extrafascial hysterectomy. At the time of inclusions, routine para-aortic node dissection was not recommended in France as a result of an undefined benefit/risk balance. Therefore, it was only performed when a perioperative analysis of the SLN showed an involvement or when a para-aortic SLN was identified. There were no recommendations concerning the type of surgical approach (open or laparoscopic).
Under general anesthesia, patients were placed in lithotomy position. Two milliliters of patent blue (Bleu Patenté V; Guerbet Laboratory, Issy les Moulineaux, France) was added to 2 mL of isotonic sodium chloride solution. The solution was injected into the cervix through a 25-gauge spinal needle at the 12-, 3-, 6-, and 9-o'clock positions (1 mL per injection). Surgery was started immediately after the injection.
At the time of surgery, the pelvic and para-aortic regions were carefully inspected transperitoneally for blue lymph ducts and nodes, as well as for suspicious enlarged nodes. The peritoneum of the pelvic sidewall was incised, and the paravesical fossae were developed for further inspection and identification of blue channels and/or blue nodes. When localized, each SLN was removed separately and sent to the pathology laboratory. The anatomical locations were recorded as follows: interiliac, obturator, external iliac, common iliac, and para-aortic areas. Then, the surgical treatment including a full external iliac and obturator dissection (level 1 according to Querleu and Morrow 26 ) and hysterectomy with bilateral salpingo-oophorectomy was performed.
Pathologic Examination
All nodes were examined by a gynecopathologist. The nodes that were obviously metastatic were sectioned. Normalappearing sentinel nodes were cut perpendicular to their long axis, then each half sentinel node was sectioned at 200-KM intervals. Odd sections were used for hematoxylin-and-eosin staining, and the middle block section was analyzed by immunohistochemistry with the broad-spectrum monoclonal antibody AE1/AE3 (Cytokeratin AE1/AE3; Dako, Glostrup, Denmark). Nonsentinel lymph nodes were assessed according to routine hematoxylin-and-eosin staining.
Algorithm Description
Because of disappointing results and the initiation of a trial based on dual labeling method 16 , the study was aborted and data remained unpublished, until we retrospectively evaluated the accuracy of the previously described SLN algorithm as depicted in Figure 1 . In our approach, each hemipelvis is considered as a unit. In both sides, we considered the following sequence: (1) pelvic node area is inspected for removal of all mapped SLN and (2) excision of every suspicious non-SLN; (3) in the absence of mapping in a hemipelvis, a standard ipsilateral lymphadenectomy is then performed. In the case of a mapping, no further lymph node dissection is performed regardless of nodal involvement.
Statistic Analysis
We recorded the position for each sentinel node. The SLN detection rate corresponds to the proportion of cases in which at least one SLN was removed among patients. A true negative was defined as a negative SLN or algorithm in a patient with no nodal involvement. A false-negative case was defined as the existence of nonsentinel nodal involvement in a lymphadenectomy area, whereas the corresponding SLNs or algorithm were negative. A true positive was defined as a positive SLN or algorithm in a patient with nodal metastases. False-positive results were impossible by definition. The falsenegative rate was defined as the proportion of procedures with negative SLN or algorithm among procedures with any positive lymph node(s). The negative predictive value (NPV) was calculated by dividing the number of true negatives by the number of negative tests (SLN or algorithm).
RESULTS
Sixty-six patients with pre-operative stage I endometrial cancer underwent sentinel node procedure between May 2003 and June 2009. Forty-three surgeries were performed at the Cancer Care Institute 11 at the Academic Hospital, and 12 surgeries were performed in private institutions.
Characteristics of patients and diseases are shown in Table 1 . Fifty-five patients (83.3%) underwent laparoscopic surgery, and the 11 remaining cases (16.7%) were managed by laparotomy. No anaphylactic reaction to patent blue occurred.
Sentinel Node Mapping Results
At least 1 sentinel node was identified in 41 patients (62.1%). A total of 74 sentinel nodes were removed, with a mean T SD number of 1.8 T 0.64 sentinel nodes per patient. Their anatomic locations are reported in Table 2 . Thirty-eight sentinel nodes (51.3%) were located in the right pelvis, and 36 sentinel nodes (48.7%) were located in the left pelvis. None was identified in the para-aortic area. Sentinel nodes were mostly found in the interiliac area and the obturator fossa. They were identified on both sides in 23 patients (56.1%). Figure 2 summarizes the distribution of identified sentinel nodes and their percentages at each site.
Final Pathologic Findings
All patients had a preoperative diagnosis of endometrial cancer confirmed on final analysis. Postoperative stage IA was the most frequent, as shown in Table 1 . Lymphovascular invasion was identified on final pathology in 12 patients (18.2%) and peritoneal washing was positive in 3 patients (4.5%).
A total of 926 lymph nodes were removed: 453 in the right pelvis (48.9%), 433 in the left pelvis (46.8%), and 40 in para-aortic area (4.3%). The mean T SD lymph node count was 14 T 6.35 per patient. Twenty-four lymph nodes (3.7%) were involved, of which only 5 (0.8%) were sentinel nodes. They were all located in the pelvic region.
Seven patients (10.6%) had positive lymph nodes. Among these 7 patients, 1 patient had a low-risk early-stage disease, 4 patients had intermediate or high-risk early-stage cancer, and 2 patients had advanced disease. Table 3 details their pathological characteristics.
In 2 of the 7 patients with positive nodes, sentinel node detection had failed. In the 5 patients with identified sentinel nodes, 2 false-negative cases were observed. The false-negative rate was thus computed at 40%, sensitivity at 60%, and NPV at 94.7%.
We applied the SLN algorithm to the whole population (n = 66) and captured 6 of the 7 cases with nodal involvement. There was 1 false negative left, yielding a false-negative rate of 14.3%, sensitivity of 85.7%, and NPV of 98.3%. In this patient, 1 SLN was removed in the right obturator fossa and showed no evidence of metastasis after pathologic examination. No suspicious lymph node was described in the right hemipelvis. However, ipsilateral lymphadenectomy revealed that 1 non-SLN was involved. In the opposite side, mapping showed neither abnormalities nor blue diffusion, and the lymph nodes harvested were negative.
The performance of the SLN procedure alone is compared to the SLN algorithm in Table 4 . According to data retrospectively collected, 70 pelvic lymphadenectomies among the 132 performed could have been avoided using such an algorithm.
DISCUSSION
Our multicentric evaluation demonstrates that SLN mapping with a cervical injection requires a dedicated adherence to SLN algorithm to lower the false-negative rate and optimize surgical staging. Indeed, the false-negative rate of the SLN algorithm is 14.3%, similar to the dual labeling method, and that such approach could avoid 53% of lymphadenectomies.
The validity of the SLN concept has been demonstrated in melanoma, breast, and vulvar cancer. 27Y29 However, the applicability of sentinel mapping to daily clinical practice and its incorporation into accepted standards depends on the detection and false-negative rates. This procedure also has to be feasible and reproducible. This is the first prospective study of SLN for endometrial cancer to our knowledge, trying to export sentinel mapping for endometrial cancer out of the research and academic institutes with nuclear medicine facilities, using therefore a simple protocol to improve feasibility. We used the intracervical injection, as it is the most reproducible technique, easy and quick to perform in the intraoperative setting.
Sentinel lymph nodes were mostly removed in the ilioobturator territories, and we did not observe any para-aortic detection. This has been previously reported in other studies using only cervical injection and remains an unsolved problem.
30Y32 Furthermore, colored detection may be difficult in this area. Our false-negative rate might thus have been underestimated. Indeed, isolated para-aortic nodal metastasis in the setting of negative pelvic nodes occur in approximately 1% of low-stage and low-grade endometrial cancers. 33 As reported in several studies, injection around the tumor or into the subserosal myometrium may enable the para-aortic sentinel node detection, compared to exclusive cervical procedure. 31, 34, 35 Although the proposed protocols, using hysteroscopy or transvaginal ultrasound-guided injection, might represent a better method to highlight the complete lymphatic drainage of the uterus, they remain clearly less applicable for physicians and might be difficult to accept for patients.
In the present article, feasibility was 100% for blue dye detection, but, as expected, the performances of SLN single labeling method were disappointing. Although our 62% detection rate is comparable with previous reports using similar protocol (57%Y62%), 22, 24 it seems much lower compared to the detection rate using a combined cervical injection. 16, 17 Somehow, combined procedure improves detection rate, which is supported by Ballester et al. 30 Indeed, using exclusive cervical injection, they found that the sentinel node detection rate was significantly lower with blue dye alone than with a dual labeling. With a false-negative rate of 40% and a low sensitivity of 60%, our protocol did not prove its accuracy in sentinel node associated a combined intracervical injection with a blue dye fundal injection. In their study, sentinel nodes were found in 36 (86%) of 42 patients, with no false-negative cases. Three percent of sentinel nodes were identified in the para-aortic level. In previous studies, Holub et al 37 had shown a significant improvement in sentinel node detection rate when subserosal injection was combined with cervical injection, compared to subserosal injection alone.
The SLN algorithm we used, previously described by Barlin et al, 25 performed much better than SLN blue dye labeling, as demonstrated by a sensitivity of 85.7%, a high NPV of 98.3%, and a decreased false-negative rate of approximately 14%. These data are comparable to those described in the prospective multi-institution trial SENTI-ENDO 18 and the more recent study reported by How et al, 19 both based on a dual labeling method using blue dye and radiocolloid. The results published by Barlin et al 25 are even better; nevertheless, their cohort was much more heterogeneous with multiple injection sites and several cases of dual labeling detection method (Table 5) . Furthermore, all procedures were performed in a single institution, with 492 reported cases; and Khoury-Collado et al 36 have previously shown that increased experience led to better detection and false-negative rates. Our cohort was more homogenous regarding SLN detection protocol. However, multicentric design and low number of inclusions have probably affected the expertise of surgeons for SLN procedure.
According to our data, the SLN algorithm would have helped avoiding 70 pelvic node dissections; and therefore, 62 would have remained necessary, considering each hemipelvis as a unit. This result might be underestimated because of the retrospective implementation of the surgical algorithm. Indeed, we focused mainly on the surgery reports, looking for upper-sized or macroscopically suspicious non-SLNs; and in some cases, this information might have been lacking because it was not crucial for the attending surgeon to report it. Indeed, our study presents several limitations. First, the use of cervical injection and a blue dye single labeling method may have hindered para-aortic detection. It is still unclear if an additional subserosal injection would have increased the mapping in this area and might be assessed in further studies. Second, the SLN algorithm was retrospectively applied, and part of the data were collected from surgery reports. Third, the lack of experience of participating surgeons due to the multicentric setup and the low number of inclusions did take part of the disappointing results of SLN procedure. However, it underlines reliability and accuracy of the SLN algorithm that performed much better than SLN alone in such a context. In conclusion, modalities of surgical treatment for clinical early-stage endometrial cancer are more than ever uncertain. MRC ASTEC and Benedetti Panici et al trials did not give evidence of therapeutic benefit of pelvic lymphadenectomy, although some flaws in their design and completion reduce the strength of their conclusions. Despite these findings, patients without nodal exploration may be over-or undertreated. Sentinel lymph node mapping may then provide an ideal midterm, reducing the unnecessary complete lymph node dissections without understaging the patients. However, the low bilateral detection rates and the nuclear medicine requirements represent obvious obstacles to the spread of the technique. In this context, our study in line with previous reports demonstrates that nodal staging could be performed using a rigorous SLN algorithm including SNL blue dye labeling method. Our approach, while presenting some limitations, has been implemented in a multicentric setting, and its relevance should now be confirmed in a prospective trial. 
